You searched for "macula"

687 results found

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Rebound phenomenon after IVT triamcinolone acetonide for macular oedema

In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...

Traumatic macular holes: reconstructive changes in foveal microstructures and visual predictor analysis, following surgical repair

The purpose of this paper was to investigate the reconstructive changes in foveal microstructures postoperatively and analyse the visual predictors in eyes with surgically closed traumatic macular holes (TMHs). This retrospective study analysed the data collected from 71 eyes of...

DRIL after macular oedema treatment in BRVO

The authors report the analysis of a single-site, retrospective, cross-sectional study to evaluate the association between disorganisation of the retinal inner layers (DRIL) and visual acuity (VA) after anti-VEGF treatment for macular oedema (MO) due to branch retinal vein occlusion...

Intravitreal dexamethasone implant for recurrent CMO secondary to IGS

In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...

Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO

This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...

OCT angiography and retinal vein occlusions

In this retrospective, observational case series, the authors set out to evaluate the morphology of the superficial and deep capillary plexa of eyes that suffered a retinal vein occlusion (RVO) on OCT angiography (OCTA) and compare the findings with fluorescein...

Neurofibromatosis type 1 features

The aim in this study was to identify the incidence and de nova mutation rate of Neurofibramatosis type 1 (NF1) and describe the ocular and non-ocular findings in a population-based cohort of patients diagnosed over a 30-year period. The study...

Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions

The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...

Artistic vibes in Beijing

For many of us all around the world, art is a form of storytelling, whether we link it to our work, our hobbies or our dreams. As a teenager growing up in the 90s, I loved ballet in high school....

Intravitreal afibercept and ranibizumab for PCV

This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...

What's trending Apr/May 2021

A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #COVID-19prevention #spectacles Ocular transmission of COVID-19 was discussed from the very beginning of the pandemic [1-3]. Indeed, it was an Ophthalmologist,...